



Alessandro Armuzzi, MD, PhD
IRCCS Humanitas Research Hospital
Milan, Italy

Professor Alessandro Armuzzi leads the Inflammatory Bowel Disease (IBD) Unit and co-leads the IBD Center at IRCCS Humanitas Research Hospital in Milan, Italy. He is also a Full Professor of Gastroenterology and Director of the Gastroenterology Residency Program at Humanitas University in Milan.

Professor Armuzzi trained at the University of Bologna and the Catholic University of Rome, Italy, and subsequently completed advanced research and clinical training in IBD at the John Radcliffe Hospital, Oxford University Hospitals, in the United Kingdom.

His research interests include the design of real-world trials and observational studies in IBD; clinical and biological predictors and outcomes in IBD and other immune-mediated diseases; diagnostic modalities for assessing disease activity in IBD; advanced therapies for IBD; dietary lipids and intestinal fibrotic processes in Crohn's disease; and biomarkers of the gut-brain axis in IBD.

He is the author of more than 480 scientific papers published in peer-reviewed journals with an impact factor, with a Scopus h-index of 71 and more than 23,000 citations.

Professor Armuzzi has held several leadership roles in national and international gastroenterology associations. These include membership on the Scientific Committee of the Italian Society of Gastroenterology (SIGE, 2014-2017); roles within the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD), including Chair from 2018 to 2019 and EduCom Chair from 2020 to 2021 and again from 2024 to 2027; and multiple positions within the European Crohn's and Colitis Organisation (ECCO), including Chair of the Clinical Research Committee (ClinCom) from 2015 to 2017, Internal Auditor from 2019 to 2020, General Secretary from 2021 to 2024, and President-elect since 2025.



Raja Atreya, MD
University Hospital of Erlangen
Erlangen, Germany

Raja Atreya is Professor of Translational Immunology in IBD and Head of the Inflammatory Bowel Disease (IBD) Unit and Clinical Study Centre at the University Hospital Erlangen in Germany. Professor Atreya received both his initial degree and his MD, for which he graduated summa cum laude, from the medical school of the Johannes Gutenberg University of Mainz in Germany. He then went on to work as a physician at the University Medical Centre, and subsequently participated in the postgraduate program on antigen-specific immunotherapy. In 2010, he was appointed as Professor for IBD at the University Hospital Erlangen, and was appointed to his current post in 2016. He heads the IBD and Clinical Study Centre at the University Hospital of Erlangen.

Professor Atreya's research work focuses on the identification of response predictors (e.g. molecular endoscopy) and resistance mechanisms to advanced therapies in IBD, as well as novel therapies and molecular targets. He recently turned his focus also on cellular therapies in IBD. He has received many awards in the course of his career including: the Paul Ehrlich and Ludwig Darmstaedter Prize for Young Researchers from the Paul Ehrlich Foundation; and the Rising Star Award from the United European Gastroenterology Federation (UEG). He has published widely, with articles as first or senior-author in peer-reviewed journals including N Engl J Med, Nature Medicine, Nature Reviews Gastroenterology & Hepatology, The Lancet Gastroenterology and Hepatology, Gastroenterology, Gut, and Journal of Crohn's and Colitis.



Remo Panaccione, MD, FRCPC

University of Calgary
Calgary, Canada

Professor Remo Panaccione is Professor of Medicine and Director of the Inflammatory Bowel Disease (IBD) Unit at the University of Calgary. He also serves as Dean of MD Admissions, directs the university's IBD Fellowship Program, and holds the Crohn's and Colitis Canada Endowed Research Chair in Inflammatory Bowel Disease.

An internationally recognized clinician, educator, and investigator, Professor Panaccione has received numerous honours, including appointment as a Canadian Association of Gastroenterology Visiting Professor, the 2020 Crohn's and Colitis Canada Outstanding Physician of the Year Award, and the 2024 Research Leadership Award. He has also been recognized as a Clarivate Highly Cited Researcher, placing him among the top 1% of researchers worldwide by citations.

His research focuses on the design, conduct, and interpretation of clinical trials in IBD, with particular emphasis on advanced therapies and optimizing patient outcomes. He has authored more than 500 peer-reviewed publications, including articles in The New England Journal of Medicine, The Lancet, Nature, Gastroenterology, and Gut.